Basecare Awarded the 2021 Science and Technology Innovation Policy Funding of Suzhou Biomedical Industry
Recently, the first batch of municipal funds of the policy support for science and technology innovation in Suzhou biomedical industry in 2021 was realized. Suzhou Basecare Medical Corporation Limited (hereafter “Basecare”) obtained the top-level subsidy of 3 million yuan by the innovative R&D result of the first PGS kit approved for the registration certificate of Class III medical devices in China.
"This is an embryo and the whole chromosome of the whole genome will be detected. If the chromosome is normal, then we will choose one that does not carry the disease-causing gene and implant it, so that the child can have a completely healthy chromosome. "In Basecare, Dr. Liang Bo, founder and chairman, showed the reporter the PGT project carried out by Basecare.
In Suzhou Biomedical Industrial Park, Basecare has set up a complete platform of assisted reproductive technology, which can realize eugenics through PDG/PGS.
In February 2020, the PGT-A kit independently developed by us became the first PGT product approved by the NMPA, which reflects domestic innovation and our leading position in the world. After more than 4 years of clinical trials and tests by over 30,000 clinical embryo samples, this product can effectively improve the clinical pregnancy rate of IVF and reduce the abortion rate. During this period, Basecare undertook the research and development of PGS standard product, and was also the only enterprise that participated in the formulation of the Technical Evaluation Guide for Quality Control of Preimplantation Chromosomal Aneuploidy Detection Reagents (high-throughput sequencing), which filled the blank of industry norms in China.
By virtue of the technological innovation, Basecare obtained the top-level subsidy of 3 million yuan in Science and Technology Innovation Policy Support of Suzhou Biomedical Industry.
In the opinion of Dr. Liang Bo, nowadays, an industrial cluster gradually formed in Suzhou Industrial Park which is also the best among all biomedical industrial parks in China in terms of business environment and innovation ability.
“The guiding role of the subsidy counts more. The government subsidies lead more investors, industries (funds), and clinical institutions to recognize us, which is very important”, said Dr. Liang Bo.
Basecare, listed on the main board of the Hong Kong Stock Exchange (stock code: 2170HK), is a leading provider of PGT clinical solutions in China. Our mission is to help infertile patients have their own babies and patients with genes of genetic diseases have healthy babies so that more families have healthy babies through the R&D and clinical application of high-throughput sequencing technology.
Apart from the absolute advantages in PGT, we have built an integrated experimental platform solution from testing reagents to embryo storage and realized the automatic and domestic hardware upgrading in assisted reproduction, and built a R&D and manufacturing center of high-end reproductive equipment. We are developing a variety of intelligent instruments, including NGS sequencer (DA500) and cryostorage system (BSG800A)
We will complete the registration and certification of the product line covering the full reproductive cycle and become a global leader in genetic technology to provide comprehensive PGT solutions for clinical institutions.
We are a unicorn enterprise with our headquarters and innovations in Suzhou. We will build a headquarter of over 70,000 square meters in Suzhou Industrial Park, which is scheduled to be completed by the end of 2022 and more than 40,000 square meters will be used to build a nationwide IVD industry chain and upstream and downstream clusters of high-end equipment manufacturing. Over 30,000 square meters will be used to build an international incubation platform for the introduction and transformation of advanced technologies. In addition, we will introduce 2 to 3 academician teams, establish a global top KOL scientific consultant team, continue to increase R&D investment and accelerate technological innovation breakthroughs to promote China’s assisted reproduction market to the international level which will benefit patients around the world.